Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 7—July 2023
Research

Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada

Rajesh Abraham Jacob, Ali Zhang1, Hannah O. Ajoge1, Michael R. D'Agostino1, Kuganya Nirmalarajah, Altynay Shigayeva, Wael L. Demian, Sheridan J.C. Baker, Hooman Derakhshani, Laura Rossi, Jalees A. Nasir, Emily M. Panousis, Ahmed N. Draia, Christie Vermeiren, Jodi Gilchrist, Nicole Smieja, David Bulir, Marek Smieja, Michael G. Surette, Andrew G. McArthur, Allison J. McGeer, Samira Mubareka, Arinjay Banerjee, Matthew S. Miller, and Karen MossmanComments to Author 
Author affiliations: McMaster University, Hamilton, Ontario, Canada (R.A. Jacob, A. Zhang, H.O. Ajoge, M.R. D'Agostino, W.L. Demian, S.J.C. Baker, L. Rossi, J.A. Nasir, E.M. Panousis, A.N. Draia, D. Bulir, M. Smieja, M.G. Surette, A.G. McArthur, M.S. Miller, K. Mossman); Sunnybrook Research Institute, Toronto, Ontario, Canada (K. Nirmalarajah, S. Mubareka); University of Toronto, Toronto (A. Shigayeva, C. Vermeiren, A.J. McGeer, S. Mubareka, A. Banerjee); University of Manitoba, Winnipeg, Manitoba, Canada (H. Derakhshani); Research Institute of St. Joe’s Hamilton, Hamilton (J. Gilchrist, N. Smieja, D. Bulir); Vaccine and Infectious Disease Organization, Saskatoon, Saskatchewan, Canada (A. Banerjee); University of Saskatchewan, Saskatoon (A. Banerjee); University of Waterloo, Waterloo, Ontario, Canada (A. Banerjee); University of British Columbia, Vancouver, British Columbia, Canada (A. Banerjee)

Main Article

Figure 3

Sensitivity of SARS-CoV-2 lineage variants to neutralizing antibodies, Canada. A–C) Sensitivity of SB3, R.1 645, and B.1.351 (Beta) variants to neutralizing antibodies from patients infected with the ancestral virus (wave 1 samples). D–F) Sensitivity of SB3, R.1 645, and B.1.351 (Beta) VoC to neutralizing antibodies from patients infected with the B.1.1.7 (Alpha) VoC (wave 3 samples). For each isolate, we tested 3 different PFU per well: 15,000 (A, D), 1,500 (B, E), and 150 (C, F). Statistical significance was calculated using 1-way analysis of variance with Tukey multiple comparisons test. ID50, 50% inhibitory dilution; PFU, plaque-forming units.

Figure 3. Sensitivity of SARS-CoV-2 lineage variants to neutralizing antibodies, Canada. A–C) Sensitivity of SB3, R.1 645, and B.1.351 (Beta) variants to neutralizing antibodies from patients infected with the ancestral virus (wave 1 samples). D–F) Sensitivity of SB3, R.1 645, and B.1.351 (Beta) VoC to neutralizing antibodies from patients infected with the B.1.1.7 (Alpha) VoC (wave 3 samples). For each isolate, we tested 3 different PFU per well: 15,000 (A, D), 1,500 (B, E), and 150 (C, F). Statistical significance was calculated using 1-way analysis of variance with Tukey multiple comparisons test. ID50, 50% inhibitory dilution; PFU, plaque-forming units.

Main Article

1These authors contributed equally to this article.

Page created: May 08, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external